| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.18 | 0.3 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.059 | 0.3 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.3 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |